Lu AF35700 (Lundbeck) has a novel pharmacological profile as a dopamine D1 and D2 antagonist with a high occupancy of 5-HT2A and 5-HT6 serotonin receptors. The relatively low D2 receptor occupancy of Lu AF35700, compared to at the D1 receptor, is expected to result in a diminished burden of side effects such as depressed mood, extrapyramidal symptoms, prolactin elevation, and anhedonia.
Lu AF35700 is a novel prospect for treatment-resistant schizophrenia. The drug is designed to be well tolerated compared to existing atypical antipsychotic therapies, hence Lundbeck is positioning its pipeline drug to help address unmet need in the schizophrenia market. The author awaits further developments for Lu AF35700, as available clinical trial data are limited to Phase I thus far.
Lu AF35700: Schizophrenia
List of Figures
Figure 1: Lu AF35700 for schizophrenia - SWOT analysis
List of Tables
Table 1: Lu AF35700 drug profile
Table 2: Lu AF35700 Phase II and Phase III trials in schizophrenia